Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Gilead Continues To Add To IO Armamentarium In Collaboration With Gadeta

Executive Summary

Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.

Advertisement

Related Content

J.P. Morgan Roundtable: Making Deals And Managing Alliances As Technologies Advance
J.P. Morgan Roundtable: Financing Challenges, And Opportunities, For Complex Therapies
Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO
Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb
Pharma's 2018 Deal-Making Story, So Far
Norgine Holds Out Cetilistat Hope As Takeda Alliance Ends In Challenging Japan Market
Aurobindo Aims For Europe Growth With Apotex Acquisitions
Roivant Cuts Jobs, Reallocates Staff As It Prepares To Put New Stars In The Spotlight
Vical Faced With Failure of Another Vaccine Trial
Stumble For Vical/Astellas CMV Vaccine In Kidney Transplants

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123449

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel